"FDA's approval of IMAAVY TM (nipocalimab-aahu) is an important step in expanding treatment options for people living with myasthenia gravis,” said Donald S. Wood, PhD, President and CEO, MDA. "With ...

“FDA’s approval of IMAAVYTM (nipocalimab-aahu) is an important step in expanding treatment options for people living with myasthenia gravis,” said Donald S. Wood, PhD, President and ...

Editor's notes: a. Ms. Masterson has not been paid for any media work. b. MG-ADL (Myasthenia Gravis-Activities of Daily Living) provides a rapid clinical assessment of the patient's recall of ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New Jersey drugmaker is confident that a broad label will land its product an ...

Notably, the FDA granted approval for IMAAVY, a new monoclonal antibody treatment for generalized myasthenia gravis, potentially strengthening J&J's portfolio in autoimmune conditions ...

The term 'Congenital' refers to 'at birth.' Congenital Heart Disease (CHD) is defined as a structural problem with the heart that a person is born with. According to experts, this problem is ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Imaavy plus standard of care led to improvements at ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle ...

The US Food and Drug Administration (FDA) has approved nipocalimab-aahu (Imaavy, Johnson & Johnson) for the treatment of generalized myasthenia gravis (gMG) in adults and adolescents 12 years of ...

On April 30, 2025, the FDA approved nipocalimab-aahu (Imaavy; Johnson & Johnson), a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis (gMG) in adult and ...

The FDA has approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu) for the treatment of treatment of generalized myasthenia gravis (gMG). Following FDA Priority Review designation, this approval ...

The drug, which J&J will sell as Imaavy, was cleared by the FDA to treat adults and children 12 years of age or older who have an autoimmune condition known as generalized myasthenia gravis. The ...